Glucagonoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) |
|||
| Line 7: | Line 7: | ||
* [[Somatostatin|Somatostatin analogs]] ([[octreotide]]) are the treatment of choice to control symptoms.<ref name="pmid25489112">{{cite journal| author=Rosenbaum A, Flourie B, Chagnon S, Blery M, Modigliani R| title=Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. | journal=Digestion | year= 1989 | volume= 42 | issue= 2 | pages= 116-20 | pmid=2548911 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2548911 }}</ref> | * [[Somatostatin|Somatostatin analogs]] ([[octreotide]]) are the treatment of choice to control symptoms.<ref name="pmid25489112">{{cite journal| author=Rosenbaum A, Flourie B, Chagnon S, Blery M, Modigliani R| title=Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. | journal=Digestion | year= 1989 | volume= 42 | issue= 2 | pages= 116-20 | pmid=2548911 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2548911 }}</ref> | ||
* [[Doxorubicin]] and [[streptozotocin]] have also been used successfully to selectively damage [[alpha cells]] of the pancreatic islets. | * [[Doxorubicin]] and [[streptozotocin]] have also been used successfully to selectively damage [[alpha cells]] of the pancreatic islets. | ||
====Drug regimen==== | |||
400 micrograms/day | |||
=== Metastasis therapy === | === Metastasis therapy === | ||
Revision as of 13:36, 12 October 2017
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Glucagonoma medical therapy |
|
Risk calculators and risk factors for Glucagonoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
The predominant medical therapy for primary glucagonoma is somatostatin analogs (octreotide). Metastatic tumors need hepatic artery embolization, Radiofrequency ablation, and molecularly therapy.
Management of primary tumor
- Somatostatin analogs (octreotide) are the treatment of choice to control symptoms.[1]
- Doxorubicin and streptozotocin have also been used successfully to selectively damage alpha cells of the pancreatic islets.
Drug regimen
400 micrograms/day
Metastasis therapy
Hepatic artery embolization
- Hepatic arterial embolization is a palliative treatment in patients with symptomatic hepatic metastases who are not candidates for surgical resection.
- Embolization can be performed via the infusion through an angiography catheter into hepatic arteries.
Radiofrequency ablation
- Ablation can be performed percutaneously or laparoscopically in patients with symptomatic hepatic metastases who are not candidates for surgical resection.
- Ablation is applicable only to smaller lesions less than 3 cm.[2]
Molecularly therapy
- Sunitinib is a radiolabeled somatostatin analog which has a role in the management of glucagonoma's that are not symptomatic or have rapidly progressive metastasis.
References
- ↑ Rosenbaum A, Flourie B, Chagnon S, Blery M, Modigliani R (1989). "Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature". Digestion. 42 (2): 116–20. PMID 2548911.
- ↑ Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC; et al. (2003). "Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience". Cancer J. 9 (4): 261–7. PMID 12967136.